send mail to support@abhimanu.com mentioning your email id and mobileno registered with us! if details not recieved
Resend Opt after 60 Sec.
By Loging in you agree to Terms of Services and Privacy Policy
Claim your free MCQ
Please specify
Sorry for the inconvenience but we’re performing some maintenance at the moment. Website can be slow during this phase..
Please verify your mobile number
Login not allowed, Please logout from existing browser
Please update your name
Subscribe to Notifications
Stay updated with the latest Current affairs and other important updates regarding video Lectures, Test Schedules, live sessions etc..
Your Free user account at abhipedia has been created.
Remember, success is a journey, not a destination. Stay motivated and keep moving forward!
Refer & Earn
Enquire Now
My Abhipedia Earning
Kindly Login to view your earning
Support
On December 22, 2021, US health regulators authorized the first pill (a drug by Pfizer) against Covid-19.
Key Points
About Pfizer drug: Paxlovid
The drug called Paxlovid is a fast and cheap way to treat early Covid-19 infections. Nirmatrelvir drug is sold under the brand name Paxlovid. This antiviral medication has been developed by Pfizer. It acts as an orally active 3CL protease inhibitor. The drug was granted emergency use authorization by US Food and Drug Administration (FDA) to treat COVID-19 disease recently. It is not authorized for pre-exposure or post-exposure prevention of COVID-19. It can also be used for initiation of treatment in people who require hospitalization due to critical COVID-19.
Who can use this drug?
The FDA has authorized Pfizer’s drug for adults and children aged 12 and more, who have been tested positive with Covid-19. People with early symptoms and highest risks of hospitalization can use this drug. Children eligible for medication must weigh at least 40 kilograms. Patients will require a positive Covid-19 test to get a prescription.
Efficacy of Paxlovid
Paxlovid has proven effective, when provided within five days of symptoms appearing.
Please Wait..
Access to prime resources